Disease-modifying therapies for multiple sclerosis

What you need to know: Disease-modifying therapies (DMTs) early in the course of active relapsing multiple sclerosis can prevent relapses, new brain and spinal cord lesions, and worsening neurological disability; Some DMTs are associated with potentially serious adverse reactions, and careful monito...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:BMJ (Online) Ročník 363; s. k4674
Hlavní autori: De Angelis, Floriana, John, Nevin A, Brownlee, Wallace J
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England BMJ Publishing Group LTD 27.11.2018
Predmet:
Blood pressure
Case reports
Clinical decision making
Clinical trials
Copolymer 1
Cost analysis
Creatinine
Decision making
Drug dosages
Drug therapy
Echocardiography
EKG
Evidence-based medicine
Hepatitis B
HIV
Human immunodeficiency virus
Injection
Interferon
Leukoencephalopathy
Magnetic resonance imaging
Monoclonal antibodies
Multiple sclerosis
Neurology
Patient care planning
Progressive multifocal leukoencephalopathy
Thrombocytopenic purpura
Thyroid
Tuberculosis
Urea
Varicella
United Kingdom > UK
ISSN:0959-8138, 1756-1833, 1756-1833
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:What you need to know: Disease-modifying therapies (DMTs) early in the course of active relapsing multiple sclerosis can prevent relapses, new brain and spinal cord lesions, and worsening neurological disability; Some DMTs are associated with potentially serious adverse reactions, and careful monitoring is required, usually through a specialist multiple sclerosis clinic; Newer DMTs have better short term outcomes than older DMTs, but there are insufficient data about their long term effectiveness and harms. A 32 year old woman with multiple sclerosis presented to her general practitioner with a five day history of numbness and weakness in the right leg. She felt well in herself and did not describe any symptoms to suggest an intercurrent infection. She had been taking weekly intramuscular injections of interferon beta-1a for the previous 18 months and reported flu-like symptoms that could last for up to 24 hours after each dose. She asked if there was a need to change her treatment and what alternatives were available.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Report-3
ObjectType-Case Study-4
content type line 23
ISSN:0959-8138
1756-1833
1756-1833
DOI:10.1136/bmj.k4674